Samsung Biologics to build $1.45bn fifth plant at Bio Campus II
South Korean biotechnology company Samsung Biologics is set to build a fifth plant (Plant 5) near its current Songdo site, as part of its strategy to expand the
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XSouth Korean biotechnology company Samsung Biologics is set to build a fifth plant (Plant 5) near its current Songdo site, as part of its strategy to expand the
Novartis has secured the US Food and Drug Administration (FDA) approval for Tafinlar (dabrafenib) plus Mekinist (trametinib) to treat a type of low-grade glioma (LGG). Tafinlar plus Mekinist
Mediar Therapeutics has secured $85m in a Series A round co-led by Novartis Venture Fund and Sofinnova Partners, which brings the company’s total financing to $105m. Pfizer Ventures,
The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) for Pfizer and BioNTech’s Omicron BA.4/BA.5-adapted bivalent Covid-19 vaccine as a booster dose in children
Pfizer has received the US Food and Drug Administration (FDA) approval for Zavzpret (zavegepant) for the acute treatment of migraine with or without aura in adults. Zavzpret is
Sandoz, the generic and biosimilar medicines unit of Novartis, has signed a Memorandum of Understanding (MOU) to build a new biologics production plant in Lendava, Slovenia. The company
China-based Biocytogen Pharmaceuticals and Janssen Biotech, a business unit of Johnson & Johnson’s subsidiary Janssen, have entered into a non-exclusive license agreement. Under the terms of the license
US-based cancer biotechnology company Volastra Therapeutics has completed the in-licensing of Amgen’s sovilnesib (AMG650), an oral small molecule inhibitor of KIF18A. Under the terms of the agreement, Volastra
Bristol Myers Squibb (BMS) has received the European Commission (EC) full marketing authorisation for Reblozyl (luspatercept) to treat anaemia in adults with non-transfusion-dependent (NTD) beta thalassemia. Luspatercept is
Eli Lilly and Company (Lilly) has entered into a global licensing agreement with Confo Therapeutics for the latter’s investigational non-opioid pain therapy, CFTX-1554, and backup compounds. CFTX-1554 is